It is important to note that inhibitors targeting NF-κB upstream (TLRs, MyD88 et al.)and effector molecules (IFNs, IL-6) have been developed and approved to be active in diseases such as LN [31]. The gene discussed is NFKB1; the disease is lobular neoplasia.